title: Tacrolimus 0.1% ointment: is it really effective in plasma cell vulvitis? Report of four cases.
abstract: BACKGROUND
  Plasma cell vulvitis is a clinically and histologically well-characterized chronic disease that usually relapses after various topical therapies. Considering the inflammatory nature of the disease, the new topical calcineurin inhibitors have been also employed successfully in few cases of Zoon's balanitis, the corresponding male condition.
  
  
  OBJECTIVE
  The aim of our study is to evaluate the effectiveness of tacrolimus ointment in a small group of plasma cell vulvitis sufferers.
  
  
  METHODS
  4 women affected by biopsy-proved plasma cell vulvitis were enrolled, after informed consent. The topical drug was applied twice daily for 6 weeks, then tapered on the basis of the clinical results. Symptoms and objective parameters were obtained periodically at the beginning, after 6 weeks and up to the end of the topical treatment. A final biopsy was performed in 3 out of our 4 patients. The follow-up is still ongoing.
  
  
  RESULTS
  The comparative analysis of subjective, objective and histopathological data has shown discordant and less encouraging results than those reported for the corresponding male condition.
  
  
  CONCLUSIONS
  At the moment, topical tacrolimus could be considered an alternative treatment for plasma cell vulvitis only in cases resistant to conventional therapies.
authors.affiliation: Department of Clinical and Experimental Medicine, Dermatology Section, University of Ferrara, Ferrara, Italy. vri@unife.it
authors.forename: Annarosa
authors.initials: A
authors.lastname: Virgili
authors.forename: Lucia
authors.initials: L
authors.lastname: Mantovani
authors.forename: Maria Michela
authors.initials: MM
authors.lastname: Lauriola
authors.forename: Andrea
authors.initials: A
authors.lastname: Marzola
authors.forename: Monica
authors.initials: M
authors.lastname: Corazza
mesh_terms: D000287:Administration, Topical; D000368:Aged; D065095:Calcineurin Inhibitors; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010950:Plasma Cells; D016559:Tacrolimus / Q000008:administration & dosage*; D016896:Treatment Outcome; D014844:Vulva / Q000473:pathology; D014847:Vulvitis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016559:Tacrolimus